ALXO Latest Press Releases

-- September 2, 2026 --

ALX Oncology to Present at Upcoming Investor Conferences in September Globe Newswire 8:00 AM

-- August 6, 2026 --

ALX Oncology Reports Second Quarter 2026 Financial Results and Provides Corporate Update Globe Newswire 8:00 AM

-- June 30, 2026 --

ALX Oncology Reports Inducement Grant as permitted by the Nasdaq Listing Rules Globe Newswire 4:40 PM

ALX Oncology Appoints Scott Garland as Chairman of the Board and Michael Listgarten as General Counsel Globe Newswire 8:00 AM

-- June 1, 2026 --

ALX Oncology to Present at the 2026 Jefferies Global Healthcare Conference in New York Globe Newswire 8:00 AM

-- May 8, 2026 --

ALX Oncology Reports First Quarter 2026 Financial Results and Provides Corporate Update Globe Newswire 8:00 AM

-- May 7, 2026 --

ALX Oncology's Evorpacept in Combination with Zanidatamab Generates Promising, Durable Response in Patients with Advanced HER2-Positive Breast Cancer and High CD47 Expression Globe Newswire 8:00 AM

-- April 30, 2026 --

ALX Oncology Announces That CD47 Biomarker Data from Clinical Trial Evaluating Evorpacept + Zanidatamab Combination in Advanced Breast Cancer Will Be Presented at ESMO Breast Cancer 2026 Globe Newswire 8:00 AM

-- April 17, 2026 --

ALX Oncology Reports Inducement Grant as permitted by the Nasdaq Listing Rules Globe Newswire 4:05 PM

-- April 13, 2026 --

ALX Oncology Appoints Jeff Knight as Chief Development and Operating Officer Globe Newswire 8:30 AM

Market Data Delayed 15 Minutes

Questions? Feedback?Olark live chat software